Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 172,912,640
  • Shares Outstanding, K 2,375,500
  • Annual Sales, $ 50,387 M
  • Annual Income, $ 17,783 M
  • 36-Month Beta 0.68
  • Price/Sales 3.48
  • Price/Book 2.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.45 unch
on 01/17/17
74.44 -4.02%
on 01/10/17
-0.33 (-0.46%)
since 12/16/16
3-Month
66.93 +6.75%
on 12/08/16
76.39 -6.47%
on 10/18/16
-4.13 (-5.46%)
since 10/17/16
52-Week
66.93 +6.75%
on 12/08/16
83.58 -14.51%
on 07/22/16
-8.78 (-10.94%)
since 01/15/16

Most Recent Stories

More News
Research and Markets - Global Multiple Myeloma Drugs Market 2017-2021 with Amgen, Celgene, Johnson & Johnson, Novartis & Takeda Pharmaceuticals Dominating

DUBLIN, Jan 16, 2017 /PRNewswire/ --

Research and Markets - Global Multiple Myeloma Drugs Market 2017-2021 with Amgen, Celgene, Johnson & Johnson, Novartis & Takeda Pharmaceuticals Dominating

Research and Markets has announced the addition of the "Global Multiple Myeloma Drugs Market 2017-2021" report to their offering.

Novartis to Conduct Trial on Obese, Type II Diabetes Patients

In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes....

ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin...

Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR

ALBANY, New York, January 12, 2017 /PRNewswire/ --

Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR

Several market players are collaborating with local and well-established companies and research facilities to strengthen their position. Transparency Market Research has observed that companies will continue...

Cardax Appoints Global Healthcare Executive as Independent Director

Cardax, Inc. ("Cardax") (OTCQB:CDXI) announced today the appointment of Michele Galen, an attorney and former Chief Communications Officer for both Novartis AG and Shire plc, as an independent...

Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.

Teva Falls on Disappointing 2017 Sales & Earnings Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 72.96
1st Resistance Point 72.68
Last Price 71.48
1st Support Level 72.20
2nd Support Level 72.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.